Grace Therapeutics Q1 2026 Earnings Report

Grace Therapeutics EPS Results

• Actual EPS: -$0.21
• Consensus EPS: -$0.22
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Grace Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Grace Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 8/12/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 12, 2025
• Conference Call Time: 4:00PM ET

Grace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways.

Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.